Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

Segment reporting (Tables)

6 Months Ended

Jan. 31, 2015

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended January 31, 2015
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	14,725			—			—			—		$	14,725
Product revenues		—		$	7,723			—			—			7,723
Royalty and license fee income		—			644			—			—			644
		14,725			8,367			—			—			23,092
Operating expenses:
Cost of clinical laboratory services		9,246			—			—			—			9,246
Cost of product revenues		—			3,818			—			—			3,818
Research and development		—			635		$	199			—			834
Selling, general and administrative		5,089			2,704			—		$	1,877			9,670
Provision for uncollectible accounts receivable		658			(57	)		—			—			601
Legal fee expense		41			(53	)		—			2,816			2,804
Total operating expenses		15,034			7,047			199			4,693			26,973

Operating income (loss)		(309	)		1,320			(199	)		(4,693	)		(3,881	)

Other income (expense)
Interest		(12	)		5			—			(42	)		(49	)
Other		4			(29	)		—			8			(17	)
Foreign exchange loss		—			(259	)		—			—			(259	)
Income (loss) before income taxes	$	(317	)	$	1,037		$	(199	)	$	(4,727	)	$	(4,206	)

Depreciation and amortization included above	$	357		$	555		$	1		$	22		$	935

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—		$	1			—			—			1
Selling, general and administrative		12			3			—		$	87			102
Total	$	14		$	4			—		$	87		$	105

Capital expenditures	$	338		$	51		$	—		$	—		$	389

Three months ended January 31, 2014
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	13,848			—			—			—		$	13,848
Product revenues		—		$	8,054			—			—			8,054
Royalty and license fee income		—			1,026			—			—			1,026
		13,848			9,080			—			—			22,928
Operating expenses:
Cost of clinical laboratory services		9,292			—			—			—			9,292
Cost of product revenues		—			3,865			—			—			3,865
Research and development		3			543		$	286			—			832
Selling, general and administrative		4,981			3,318			—		$	1,785			10,084
Provision for uncollectible accounts receivable		920			(8	)		—			—			912
Legal fee expense		142			15			—			1,339			1,496
Total operating expenses		15,338			7,733			286			3,124			26,481

Operating income (loss)		(1,490	)		1,347			(286	)		(3,124	)		(3,553	)

Other income (expense)
Interest		(11	)		3			—			(44	)		(52	)
Other		9			(6	)		—			12			15
Foreign exchange gain		—			20			—			—			20
Income (loss) before income taxes	$	(1,492	)	$	1,364		$	(286	)	$	(3,156	)	$	(3,570	)

Depreciation and amortization included above	$	355		$	621		$	2		$	24		$	1,002

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—			—			—			—			—
Selling, general and administrative		9		$	5			—		$	93			107
Total	$	11		$	5			—		$	93		$	109

Capital expenditures	$	103		$	7		$	—		$	—		$	110

Six months ended January 31, 2015
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	30,547			—			—			—		$	30,547
Product revenues		—		$	15,725			—			—			15,725
Royalty and license fee income		—			1,644			—			—			1,644
		30,547			17,369			—			—			47,916
Operating expenses:
Cost of clinical laboratory services		19,376			—			—			—			19,376
Cost of product revenues		—			7,513			—			—			7,513
Research and development		—			1,183		$	442			—			1,625
Selling, general and administrative		10,157			5,853			—		$	3,945			19,955
Provision for uncollectible accounts receivable		1,189			(47	)		—			—			1,142
Legal		131			(51	)		—			5,190			5,270
Total operating expenses		30,853			14,451			442			9,135			54,881

Operating income (loss)		(306	)		2,918			(442	)		(9,135	)		(6,965	)

Other income (expense)
Interest		(39	)		7			—			(86	)		(118	)
Other		6			(35	)		—			31			2
Foreign exchange gain		—			(731	)		—			—			(731	)
Income (loss) before income taxes	$	(339	)	$	2,159		$	(442	)	$	(9,190	)	$	(7,812	)

Depreciation and amortization included above	$	714		$	1,113		$	2		$	44		$	1,873

Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—		$	2			—			—			2
Selling, general and administrative		21			3			—		$	174			198
Total	$	24		$	5			—		$	174		$	203

Capital expenditures	$	589		$	64		$	—		$	—		$	653

Six months ended January 31, 2014
	Clinical Labs			Life Sciences		Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	28,707			—		—			—		$	28,707
Product revenues		—		$	15,717		—			—			15,717
Royalty and license fee income		—			2,637		—			—			2,637
		28,707			18,354		—			—			47,061
Operating expenses:
Cost of clinical laboratory services		19,001			—		—			—			19,001
Cost of product revenues		—			7,712		—			—			7,712
Research and development		14			1,069	$	566			—			1,649
Selling, general and administrative		10,031			6,813		—		$	3,768			20,612
Provision for uncollectible accounts receivable		1,764			20		—			—			1,784
Legal		290			37		—			2,550			2,877
Total operating expenses		31,100			15,651		566			6,318			53,635

Operating income (loss)		(2,393	)		2,703		(566	)		(6,318	)		(6,574	)

Other income (expense)
Interest		(22	)		8		—			(100)			(114	)
Other		27			21		—			28			76
Foreign exchange gain		—			317		—			—			317
Income (loss) before income taxes	$	(2,388	)	$	3,049	$	(566	)	$	(6,390	)	$	(6,295	)

Depreciation and amortization included above	$	710		$	1,262	$	6		$	49		$	2,027

Share-based compensation included in above:
Cost of clinical laboratory services	$	4			—		—			—		$	4
Research and development		—		$	1		—			—			1
Selling, general and administrative		19			9		—		$	179			207
Total	$	23		$	10		—		$	179		$	212

Capital expenditures	$	362		$	82	$	—		$	—		$	444

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details